Some Dialysis Humor, Part 3
Editor's Note: This is part 2 of a 3-part caregiver story, submitted to us by Joan Foster, who was a caregiver for her husband Charles' Chronic Kidney Disease (CKD). To…
Continue Reading
Some Dialysis Humor, Part 3
Repairing the Wiring: How a New Stem Cell Therapy Aims to Defeat Chronic Spinal Cord Injury
As reported on Inside Precision Medicine, for years, a chronic spinal cord injury (SCI) has felt like a permanent biological roadblock. When the spinal cord is damaged, the immediate aftermath—known…
Continue Reading
Repairing the Wiring: How a New Stem Cell Therapy Aims to Defeat Chronic Spinal Cord Injury
Huyabio’s HBI-8000 and Opdivo Combination Shows Significant Benefit in Phase 3 Melanoma Study
As reported on Fierce Pharma, Huyabio has reported encouraging Phase 3 results for its investigational oral HDAC inhibitor, HBI-8000, when used alongside Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) in patients…
Continue Reading
Huyabio’s HBI-8000 and Opdivo Combination Shows Significant Benefit in Phase 3 Melanoma Study
Megan’s Myasthenia Gravis Story: From Uncertainty to Advocacy
I was diagnosed with myasthenia gravis, or MG, in 2021 when I was in my early 20s. My journey began at a friend’s birthday party when I noticed my face…
Continue Reading
Megan’s Myasthenia Gravis Story: From Uncertainty to Advocacy
Some Dialysis Humor, Part 2
Editor's Note: This is part 2 of a 3-part caregiver story, submitted to us by Joan Foster, who was a caregiver for her husband Charles' Chronic Kidney Disease (CKD). To…
Continue Reading
Some Dialysis Humor, Part 2
AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression
As reported on PharmaBiz, AtaiBeckley has announced a key milestone in the development of its investigational depression therapy, VLS-01, with the final participant now dosed in the company’s Phase 2b…
Continue Reading
AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression
Natalie’s GACI Story
Editor's Note: Patient Worthy is honored to share this story, originally written by Anne and Jerry van Wyk, and shared with us by our friends at the Brighter Hope Foundation.…
Continue Reading
Natalie’s GACI Story
“Two Rare Diagnoses, One Common Lesson: Start with Genetic Testing”
Every day, parents just like me sit in doctors’ offices searching for answers. They know something isn’t quite right. Maybe their child isn’t meeting milestones. Maybe their development has stalled,…
Continue Reading
“Two Rare Diagnoses, One Common Lesson: Start with Genetic Testing”
New Experimental Drug Offers Hope for Mesothelioma Patients
As reported on Vermont Biz, researchers at the University of Vermont (UVM) and biotechnology company RS Oncology have reported encouraging results from an early-stage clinical trial of a novel treatment…
Continue Reading
New Experimental Drug Offers Hope for Mesothelioma Patients
2026 Alzheimer’s Update
For more than a century Alzheimer’s disease has been thought to be incurable. But a recent study published in the New England Journal of Medicine (NEJM), and reported on by…
Continue Reading
2026 Alzheimer’s Update
Some Dialysis Humor, Part 1
Editor's Note: This is part 1 of a 3-part caregiver story, submitted to us by Joan Foster, who was a caregiver for her husband Charles' Chronic Kidney Disease (CKD). Hold…
Continue Reading
Some Dialysis Humor, Part 1
FDA Issues Complete Response Letter for Rivoceranib–Camrelizumab Combination in Advanced Liver Cancer
As reported by The Manila Times, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Elevar Therapeutics regarding its new drug application for the…
Continue Reading
FDA Issues Complete Response Letter for Rivoceranib–Camrelizumab Combination in Advanced Liver Cancer
ISTH 2026: Long-Term Phase 3 Data Support Denecimig as a Flexible Prophylactic Option for Hemophilia A
As covered by Fairfax Times, Novo Nordisk has reported encouraging long-term findings for its investigational hemophilia A therapy denecimig (Mim8), with interim results from the Phase 3 FRONTIER4 extension study…
Continue Reading
ISTH 2026: Long-Term Phase 3 Data Support Denecimig as a Flexible Prophylactic Option for Hemophilia A
Heal Canada’s Summer 2026 Issue of E3 Advocacy Magazine
Our friends at Heal Canada have launched the newest edition of their magazine, E3 Advocacy! Their digital publication focuses on the importance of patient advocacy, patient stories, and bridging knowledge…
Continue Reading
Heal Canada’s Summer 2026 Issue of E3 Advocacy Magazine
FDA Grants Breakthrough Device Designation to Aurenar’s V-Link System for Preventing Cerebral Vasospasm After Brain Hemorrhage
As reported on MobiHealth News, the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Device designation to Aurenar’s V-Link System, a noninvasive neuromodulation technology designed to help reduce cerebral…
Continue Reading
FDA Grants Breakthrough Device Designation to Aurenar’s V-Link System for Preventing Cerebral Vasospasm After Brain Hemorrhage
An Interview with Allyson, a Congenital Adrenal Hyperplasia Patient
Can you take me back to when you first became aware that you had a health condition as a child. Did you overhear the adults in your life speaking about…
Continue Reading
An Interview with Allyson, a Congenital Adrenal Hyperplasia Patient
Merck Partners With ACTF to Expand Access to New HIV Treatment Through State ADAP Programs
As reported on PharmaBiz, Merck has announced a new agreement with the ADAP Crisis Task Force (ACTF) aimed at improving access to its recently approved HIV treatment, Idvynso (doravirine/islatravir), for…
Continue Reading
Merck Partners With ACTF to Expand Access to New HIV Treatment Through State ADAP Programs
GLP-1 Receptor Agonists Associated With Lower Cardiovascular and Inflammatory Risks in Hidradenitis Suppurativa
As reported on MedPage Today, large retrospective study suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may offer broad health benefits for patients with hidradenitis suppurativa (HS), extending beyond their established…
Continue Reading
GLP-1 Receptor Agonists Associated With Lower Cardiovascular and Inflammatory Risks in Hidradenitis Suppurativa
FDA Sets Early 2027 Review Deadline for Sarepta’s Duchenne Exon-Skipping Therapies Despite Confirmatory Trial Setback
As reported on BioSpace, Sarepta Therapeutics has reached an important regulatory milestone in its effort to secure traditional FDA approval for two Duchenne muscular dystrophy (DMD) treatments, Amondys 45 and…
Continue Reading
FDA Sets Early 2027 Review Deadline for Sarepta’s Duchenne Exon-Skipping Therapies Despite Confirmatory Trial Setback
Nexviazyme Achieves Key Phase 3 Milestone in Infants With Pompe Disease, Sanofi Prepares FDA Expansion Filing
As reported on Tech Times, Sanofi has reported positive results from its Phase 3 Baby-COMET study evaluating Nexviazyme (avalglucosidase alfa) in infants with infantile-onset Pompe disease (IOPD), one of the…
Continue Reading
Nexviazyme Achieves Key Phase 3 Milestone in Infants With Pompe Disease, Sanofi Prepares FDA Expansion Filing
A Doctor-Patient Interview on Ovarian Cancer
Editor's Note: Patient Worthy is honored to share this interview, featuring Kate, an ovarian cancer survivor, and Dr. Premal Thaker, M.D. “There is fear, and there are hard days, but…
Continue Reading
A Doctor-Patient Interview on Ovarian Cancer
FDA Clears Orca Bio’s Tregzi for Adults Undergoing Allogeneic Stem Cell Transplantation for Blood Cancers
As reported on PharmaBiz, the US Food and Drug Administration (FDA) has approved Orca Bio’s Tregzi, a precision-engineered cell therapy designed for use in matched-donor allogeneic hematopoietic stem cell transplantation…
Continue Reading
FDA Clears Orca Bio’s Tregzi for Adults Undergoing Allogeneic Stem Cell Transplantation for Blood Cancers
FDA Expands Casgevy Use to Children as Young as 2 Years Old
As reported on FiercePharma, the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Vertex Pharmaceuticals’ gene-editing therapy Casgevy (exagamglogene autotemcel), allowing the treatment to be used…
Continue Reading
FDA Expands Casgevy Use to Children as Young as 2 Years Old
Ascletis Advances Obesity Pipeline With Two FDA IND Filings for Long-Acting Injectable Candidates
As reported on PharmaBiz, Ascletis Pharma has announced the submission of two Investigational New Drug (IND) applications to the US Food and Drug Administration (FDA) for experimental obesity treatments designed…
Continue Reading
Ascletis Advances Obesity Pipeline With Two FDA IND Filings for Long-Acting Injectable Candidates
European Commission Expands Approval of Novartis Gene Therapy for Broader SMA Population
As reported on Pharmaceutical Technology, the European Commission has approved Novartis’ gene replacement therapy Itvisma (onasemnogene abeparvovec) for the treatment of children aged two years and older, adolescents, and adults…
Continue Reading
European Commission Expands Approval of Novartis Gene Therapy for Broader SMA Population
